<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01550835</url>
  </required_header>
  <id_info>
    <org_study_id>EV-10322</org_study_id>
    <nct_id>NCT01550835</nct_id>
  </id_info>
  <brief_title>Impact of Aspiration Thrombectomy During Carotid Stenting</brief_title>
  <official_title>Impact of Aspiration Thrombectomy During Carotid Stenting on New Ischemic Lesions Identified by Diffusion-Weighted Magnetic Resonance Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fogarty Clinical Research Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helen Kay Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northern Michigan Hospital Foundation's Louis A. and Sally Cannon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fogarty Clinical Research Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether aspiration thrombectomy following carotid
      stent deployment will reduce the number of procedure related signals as identified by
      diffusion weighted MRI of the brain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies have demonstrated that carotid artery stenting is a safe and effective alternative to
      carotid endarterectomy for high or standard risk patients with symptomatic stenosis. Despite
      the routine use of embolic protection devices, numerous studies have shown that carotid
      stenting is associated with a higher degree of intracranial emboli by diffusion-weighted MRI
      of the brain. A potential solution to minimize this effect is the use of aspiration prior to
      distal embolic protection removal.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2012</start_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of new, ischemic foci</measure>
    <time_frame>18-48 hours post procedure</time_frame>
    <description>Foci of restricted diffusion will be classified by their number, location, and size</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ischemic zone area</measure>
    <time_frame>18-48 hours post stenting</time_frame>
    <description>Maximum size of new, ipsilateral,ischemic foci on post-carotid stenting diffusion-weighted MRI of the brain</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Carotid Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>Distal Embolic Protection Only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carotid stenting with distal embolic protection only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Distal embolic protection and aspiration thrombectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspiration thrombectomy following stent deployment and prior to removal of distal embolic protection</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Emboshield NAV6® embolic protection system (Abbott Vascular, Santa Clara, CA)</intervention_name>
    <description>Standard of care use of an embolic protection device</description>
    <arm_group_label>Distal Embolic Protection Only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Emboshield NAV6® embolic protection system (Abbott Vascular, Santa Clara, CA)</intervention_name>
    <description>Aspiration thrombectomy following stent deployment and prior to embolic protection device removal</description>
    <arm_group_label>Distal embolic protection and aspiration thrombectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ICA stenosis greater than 50 percent by carotid angiography

          -  Documented hemispheric ischemic stroke, TIA, amaurosis fugax, or retinal stroke in the
             last six months ipsilateral to the stented lesion

        Exclusion Criteria:

          -  Subject less than 40 years of age

          -  Pregnant subjects

          -  Asymptomatic carotid stenosis

          -  Total occlusion of target carotid artery

          -  Inability to deploy distal protection device or stent in target vessel

          -  Allergy to both aspirin and approved thienopyridine anti-platelet drugs
             (clopidogrel/ticlopidine)

          -  Multiple carotid stenoses in same vessel that cannot be covered by single stent

          -  Ipsilateral intracranial stenosis requiring treatment

          -  Isolated common carotid stenosis

          -  Stenosis less than 50 percent by angiography

          -  Chronic or paroxysmal atrial fibrillation not treated with warfarin or dabigatran.

          -  Life expectancy less than 30 days

          -  Active bleeding diathesis

          -  Suspected Myocardial Infarction within 72 hours prior to carotid stenting

          -  Presence of intracranial tumor arteriovenous malformations or aneurysm requiring
             treatment

          -  Inability to undergo DWMRI

          -  Unwillingness to participate or provide consent

          -  Subjects using a legally authorized representative for consent for participation

          -  Concurrently enrolled in another study

          -  Stroke, TIA, amaurosis fugax ipsilateral to the treated lesion more than 6 months from
             randomization

          -  Occlusive or critical ilio-femoral disease that precludes safe femoral access to the
             aortic arch

          -  Severe atherosclerosis of the aortic arch or origin of the innominate or common
             carotid arteries

          -  Prior large stroke, multiple lacunar infarcts, or dementia

          -  Stenosis that contain visible thrombus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Joye, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fogarty Clinical Research Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Betty deBettencourt, RN</last_name>
    <phone>650-962-4566</phone>
    <email>betty.debettencourt@fogartyinstitute.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>El Camino Hospital</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betty deBettencourt, RN</last_name>
      <phone>650-962-4566</phone>
      <email>betty.debettencourt@fogartyinstitute.org</email>
    </contact>
    <investigator>
      <last_name>James Joye, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northern Michigan Regional Hospital</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <zip>49770</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Lalonde, RN</last_name>
      <phone>231-487-9185</phone>
      <email>jlalonde@cvrcnm.com</email>
    </contact>
    <investigator>
      <last_name>Jason Ricci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2012</study_first_submitted>
  <study_first_submitted_qc>March 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2012</study_first_posted>
  <last_update_submitted>April 17, 2015</last_update_submitted>
  <last_update_submitted_qc>April 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fogarty Clinical Research Inc.</investigator_affiliation>
    <investigator_full_name>James Joye</investigator_full_name>
    <investigator_title>Chief Medical Officer</investigator_title>
  </responsible_party>
  <keyword>Symptomatic carotid artery stenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

